{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:19:43Z","timestamp":1793229583171,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004755","name":"EMD Serono Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.msard.2025.106272","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T15:02:07Z","timestamp":1736866927000},"page":"106272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Real world experience with cladribine tablets for multiple sclerosis at four academic multiple sclerosis centers"],"prefix":"10.1016","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5359-6686","authenticated-orcid":false,"given":"Devon S.","family":"Conway","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline A.","family":"Nicholas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas R.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M.","family":"Mowry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Naismith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106272_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578164","article-title":"Cladribine tablets in people with relapsing multiple sclerosis: a real-world multicentric study from southeast European MS centers","volume":"382","author":"Adamec","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106272_bib0014","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ncl.2023.06.004","article-title":"Highly effective therapy versus escalation approaches in early multiple sclerosis: what is the future of multiple sclerosis treatment?","volume":"42","author":"Bou Rjeily","year":"2024","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.msard.2025.106272_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104951","article-title":"Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: the CLARENCE study","volume":"79","author":"Brownlee","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106272_bib0019","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/135245850100700610","article-title":"Factors related to agreement between self-reported and conventional Expanded Disability Status Scale (EDSS) scores","volume":"7","author":"Cheng","year":"2001","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106272_bib0009","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11136-011-9958-8","article-title":"Neuro-QOL: Quality of life item banks for adults with neurological disorders: Item development and calibrations based upon clinical and general population testing","volume":"21","author":"Gershon","year":"2012","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.msard.2025.106272_bib0002","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40120-022-00339-7","article-title":"Cladribine tablets for relapsing\u2013remitting multiple sclerosis: a clinician's review","volume":"11","author":"Giovannoni","year":"2022","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106272_bib0003","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106272_bib0004","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing\u2013remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106272_bib0008","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106272_bib0007","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-13-37","article-title":"Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis","volume":"13","author":"Learmonth","year":"2013","journal-title":"BMC. Neurol."},{"key":"10.1016\/j.msard.2025.106272_bib0001","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","article-title":"Cladribine: mode of action and implications for treatment of multiple sclerosis","volume":"34","author":"Leist","year":"2011","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.msard.2025.106272_bib0018","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-14-58","article-title":"Systematic literature review and validity evaluation of the expanded disability status scale (EDSS) and the multiple sclerosis functional composite (MSFC) in patients with multiple sclerosis","volume":"14","author":"Meyer-Moock","year":"2014","journal-title":"BMC. Neurol."},{"key":"10.1016\/j.msard.2025.106272_bib0010","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1177\/1352458515599450","article-title":"Validating Neuro-QoL short forms and targeted scales with persons who have multiple sclerosis","volume":"22","author":"Miller","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106272_bib0015","doi-asserted-by":"crossref","DOI":"10.1177\/13524585241267211","article-title":"Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis","volume":"30","author":"Roos","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106272_bib0006","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1191\/1352458502ms845oa","article-title":"The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials","volume":"8","author":"Rudick","year":"2002","journal-title":"Mult. Scler."},{"issue":"88","key":"10.1016\/j.msard.2025.106272_bib0005","first-page":"e5131","article-title":"The Multiple Sclerosis Performance Test (MSPT): an iPad-based disability assessment tool","author":"Rudick","year":"2014","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.msard.2025.106272_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105052","article-title":"Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States","volume":"79","author":"Song","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106272_bib0016","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/13524585221137502","article-title":"Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry","volume":"29","author":"Spelman","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106272_bib0017","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-8-55","article-title":"Disability status and quality of life in multiple sclerosis: non-linearity of the Expanded Disability Status Scale (EDSS)","volume":"8","author":"Twork","year":"2010","journal-title":"Health Qual. Life Outcomes"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T14:16:32Z","timestamp":1740665792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825000161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":19,"alternative-id":["S2211034825000161"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106272","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real world experience with cladribine tablets for multiple sclerosis at four academic multiple sclerosis centers","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106272","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106272"}}